The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Benjamin H. Mullish, Mohammed Nabil Quraishi, Jonathan P. Segal, Victoria L. McCune, Melissa Baxter, Gemma L. Marsden, David Moore, Alaric Colville, Neeraj Bhala, Tariq H. Iqbal, Christopher Settle, Graziella Kontkowski, Ailsa L. Hart, Peter Hawkey, Horace RT Williams, Simon D. Goldenberg*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

30 Citations (Scopus)
Original languageEnglish
Pages (from-to)S1-S31
JournalJournal of Hospital Infection
Publication statusPublished - Sep 2018

Bibliographical note

Funding Information:
There was no external funding for this work. BHM is the recipient of a Medical Research Council (MRC) Clinical Research Training Fellowship (grant reference: MR/R000875/1). BHM and HRTW receive support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.


  • Clostridium difficile
  • faecal transplant
  • inflammatory bowel disease
  • microbiota

Cite this